Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation

1Baden LR, Rubin EJ. Covid-19 - The search for effective therapy. N Engl J Med. 2020;382:1851-2. Baden LR Rubin EJ Covid-19 - The search for effective therapy N Engl J Med 20203821851 210.1056/NEJMe2005477712144632187463Search in Google Scholar

2Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383:2451-60. Berlin DA Gulick RM Martinez FJ Severe Covid-19 N Engl J Med 20203832451 6010.1056/NEJMcp200957532412710Search in Google Scholar

3Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. Prognostic risk factors in ventilator-associated pneumonia. Med Sci Monit. 2018;24:1321-8. Karakuzu Z Iscimen R Akalin H Kelebek Girgin N Kahveci F Sinirtas M Prognostic risk factors in ventilator-associated pneumonia Med Sci Monit 2018241321 810.12659/MSM.905919584871529503436Search in Google Scholar

4Grasselli G, Scaravilli V, Mangioni D, Scudeller L, Alagna L, Bartoletti M, et al. Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest. 2021;160:454–65. Grasselli G Scaravilli V Mangioni D Scudeller L Alagna L Bartoletti M et al Hospital-Acquired Infections in Critically Ill Patients With COVID-19 Chest 2021160454 6510.1016/j.chest.2021.04.002805684433857475Search in Google Scholar

5Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. Bmc Infect Dis. 2020;20:646. Sharifipour E Shams S Esmkhani M Khodadadi J Fotouhi-Ardakani R Koohpaei A et al Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU Bmc Infect Dis 20202064610.1186/s12879-020-05374-z746175332873235Search in Google Scholar

6Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27:741.e9-18. Shekar K Fraser JF Smith MT Roberts JA Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation J Crit Care 201227741e9-1810.1016/j.jcrc.2012.02.01322520488Search in Google Scholar

7Chen GJ, Lin SW, Tsai IL, Kuo CH, Wang JT, Hsieh SM. Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation. J Formos Med Assoc. 2020;119:1086-92. Chen GJ Lin SW Tsai IL Kuo CH Wang JT Hsieh SM Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation J Formos Med Assoc 20201191086 9210.1016/j.jfma.2019.10.00531672434Search in Google Scholar

8Wi J, Noh H, Min KL, et al. Population pharmacokinetics and dose optimization of teicoplanin during venoarterial extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2017;61:e01015-17. Wi J Noh H Min KL et al Population pharmacokinetics and dose optimization of teicoplanin during venoarterial extracorporeal membrane oxygenation Antimicrob Agents Chemother 201761e01015 1710.1128/AAC.01015-17557134828674057Search in Google Scholar

9Nakamura A, Takasu O, Sakai Y, et al. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections. J Infect Chemother. 2015;21:449-55. Nakamura A Takasu O Sakai Y et al Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections J Infect Chemother 201521449 5510.1016/j.jiac.2015.02.00225726436Search in Google Scholar

10Mimoz O, Rolland D, Adoun M, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/ kg per day in patients with ventilator-associated pneumonia. Intensive Care Med. 2006;32:775-9. Mimoz O Rolland D Adoun M et al Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/ kg per day in patients with ventilator-associated pneumonia Intensive Care Med 200632775 910.1007/s00134-006-0136-316550370Search in Google Scholar

11Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99110. Ulldemolins M Roberts JA Rello J Paterson DL Lipman J The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients Clin Pharmacokinet 2011509911010.2165/11539220-000000000-0000021142293Search in Google Scholar

12Shiraishi Y, Okajima M, Sai Y, Miyamoto K, Inaba H. Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin. Anaesth Intensive Care. 2012;40:442–9. Shiraishi Y Okajima M Sai Y Miyamoto K Inaba H Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin Anaesth Intensive Care 201240442 910.1177/0310057X120400030922577909Search in Google Scholar

13Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53:406979. Svetitsky S Leibovici L Paul M Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis Antimicrob Agents Chemother 20095340697910.1128/AAC.00341-09276416319596875Search in Google Scholar

14Zhang J, Ma X, Yu F, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. Biorxiv. 2020. doi:10.1101/2020.02.05.935387. [Epub ahead of print] Zhang J Ma X Yu F et al Teicoplanin potently blocks the cell entry of 2019-nCoV Biorxiv 2020 10.1101/2020.02.05.935387.[Epubaheadofprint]Open DOISearch in Google Scholar